Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.

Akihiro Nakamura,Yuta Kagaya,Hiroki Saito,Masanori Kanazawa,Kenjiro Sato,Masanobu Miura,Masateru Kondo,Hideaki Endo

Journal of atherosclerosis and thrombosis（2022）

引用 7|浏览7

暂无评分

摘要

Compared with bezafibrate, pemafibrate is more effective in decreasing TG levels and increasing Apo A-I levels and is safer regarding liver and renal function.

查看译文

关键词

Bezafibrate,Comparison of pemafibrate and bezafibrate,Pemafibrate,Peroxisome proliferator-activated receptor (PPAR)-α,Renal function,Triglycerides

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要